<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00381550</url>
  </required_header>
  <id_info>
    <org_study_id>NCI-2009-00209</org_study_id>
    <secondary_id>NCI-2009-00209</secondary_id>
    <secondary_id>J0638</secondary_id>
    <secondary_id>7704</secondary_id>
    <secondary_id>P30CA006973</secondary_id>
    <secondary_id>U01CA070095</secondary_id>
    <nct_id>NCT00381550</nct_id>
  </id_info>
  <brief_title>3-AP and Fludarabine in Treating Patients With Myeloproliferative Disorders, Chronic Myelomonocytic Leukemia, or Accelerated Phase or Blastic Phase Chronic Myelogenous Leukemia</brief_title>
  <official_title>Phase II Trial of Triapine (NSC #663249, 3-Aminopyridine-2-Carboxaldehyde Thiosemicarbone) Plus Fludarabine (NSC #312887, Fludarabine Monophosphate) in Adults With Aggressive Myeloproliferative Disorders (MPDs) Including Chronic Myelomonocytic Leukemia (CMML) and Chronic Myelogenous Leukemia in Accelerated Phase (CML-AP) or Blast Crisis (CML-BC)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This phase II trial is studying how well giving 3-AP together with fludarabine works in
      treating patients with myeloproliferative disorders (MPD), chronic myelomonocytic leukemia
      (CMML), or accelerated phase or blastic phase chronic myelogenous leukemia. Drugs used in
      chemotherapy, such as 3-AP and fludarabine, work in different ways to stop the growth of
      cancer cells, either by killing the cells or by stopping them from dividing. 3-AP may help
      fludarabine work better by making cancer cells more sensitive to the drug. 3-AP and
      fludarabine may also stop the growth of cancer cells by blocking some of the enzymes needed
      for cell growth. Giving 3-AP together with fludarabine may kill more cancer cells.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:

      I. Determine the efficacy of 3-AP (Triapine®) followed by fludarabine phosphate in patients
      with myeloproliferative disorders or chronic myelomonocytic leukemia in aggressive phase or
      transformation or chronic myelogenous leukemia in accelerated phase or blast crisis.

      II. Determine the toxicity of this regimen in these patients. III. Determine, preliminarily,
      the effect of this regimen on circulating leukemic cell genetics in these patients.

      Outline: This is an open-label study.

      Patients receive 3-AP (Triapine®) IV over 4 hours followed by fludarabine phosphate IV over
      30 minutes on days 1-5. Courses repeat every 21 days in the absence of disease progression or
      unacceptable toxicity. Patients undergo bone marrow and/or peripheral blood collection at
      baseline and periodically during study treatment for molecular analysis of Janus kinase 2
      (JAK2) mutations, GATA-1 mutations, and expression of the death-inducer-obliterator (Dido)
      genes on chromosome 20q.

      After completion of study treatment, patients are followed periodically.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2006</start_date>
  <completion_date type="Actual">March 2011</completion_date>
  <primary_completion_date type="Actual">March 2011</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Response Rate Including Complete Response, Partial Response, and Hematological Improvement Assessed by Blood Cell Counts, Number of Blasts in Bone Marrow, and Clinical Evaluation</measure>
    <time_frame>Up to 4 years</time_frame>
    <description>Bone marrow aspiration and biopsies were performed prior to treatment, during week 3 of the first cycle, at the time of hematologic recovery from all cycles of therapy (defined as neutrophil count &gt;500/mm3 and platelets &gt;20,000/mm3 independently of transfusion), or at any time that leukemia regrowth was suspected. The overall response rate was defined as complete remission, partial remission, or hematologic improvement, lasting for ≥30 days. Given the different subsets of diseases, standardized response criteria were used for CMML (the Myelodysplastic Syndrome International Working Group criteria),33 CMML transforming to acute myeloid leukemia (standard AML response criteria) , accelerated MPN (Giles et al.), and transformation of MPN to secondary AML (Mascarenhas et al.).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of Grade 3 or 4 Drug-related Non-hematologic Toxicity as Assessed by NCI CTCAE v3.0</measure>
    <time_frame>Up to 4 years</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">35</enrollment>
  <condition>Accelerated Phase Chronic Myelogenous Leukemia</condition>
  <condition>Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative</condition>
  <condition>Blastic Phase Chronic Myelogenous Leukemia</condition>
  <condition>Chronic Eosinophilic Leukemia</condition>
  <condition>Chronic Myelomonocytic Leukemia</condition>
  <condition>Essential Thrombocythemia</condition>
  <condition>Philadelphia Chromosome Negative Chronic Myelogenous Leukemia</condition>
  <condition>Polycythemia Vera</condition>
  <condition>Primary Myelofibrosis</condition>
  <condition>Relapsing Chronic Myelogenous Leukemia</condition>
  <arm_group>
    <arm_group_label>Arm I</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive 3-AP (Triapine®) IV over 4 hours followed by fludarabine phosphate IV over 30 minutes on days 1-5. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>fludarabine phosphate</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Arm I</arm_group_label>
    <other_name>2-F-ara-AMP</other_name>
    <other_name>Beneflur</other_name>
    <other_name>Fludara</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>triapine</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Arm I</arm_group_label>
    <other_name>3-AP</other_name>
    <other_name>OCX-191</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>laboratory biomarker analysis</intervention_name>
    <description>Correlative study</description>
    <arm_group_label>Arm I</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Criteria:

          -  Not pregnant or nursing

          -  Histopathologically confirmed diagnosis of 1 of the following:

               -  Myeloproliferative disorders (MPDs) in aggressive phase or transformation

               -  CML in accelerated phase or blast crisis

               -  Chronic myelomonocytic leukemia in aggressive phase (5-19% bone marrow blasts) or
                  transformation (&gt; 20% bone marrow blasts)

          -  Myeloproliferative disorders (MPDs) in aggressive phase or transformation, including
             the following:

               -  Polycythemia vera (PV)

               -  Essential thrombocythemia (ET)

               -  Myelofibrosis with myeloid metaplasia

               -  Hypereosinophilic syndrome

               -  Atypical (Philadelphia chromosome negative) chronic myelogenous leukemia (Ph-
                  CML)

          -  Patients with aggressive phase MPD (PV, ET, or Ph- CML) must meet ≥ 1 of the following
             criteria:

               -  Marrow blasts &gt; 5%

               -  Peripheral blood blasts plus progranulocytes &gt; 10%

               -  New onset or increasing myelofibrosis

               -  New onset or &gt; 25% increase in hepatomegaly or splenomegaly

               -  New onset constitutional symptoms (fever, weight loss, splenic pain, bone pain)

          -  Multilineage bone marrow failure

          -  Ineligible for established curative regimens, including stem cell transplantation

          -  ECOG performance status 0-2

          -  Negative pregnancy test

          -  Fertile patients must use effective contraception

          -  No chronic toxicity from prior chemotherapy &gt; grade 1

          -  No history of severe coronary artery disease

          -  Creatinine normal OR creatinine clearance &gt;= 60 mL/min

          -  AST and ALT =&lt; 2.5 times normal

          -  Bilirubin =&lt; 2.0 mg/dL unless due to leukemia, Gilbert's syndrome, or hemolysis

          -  No arrhythmias (other than atrial flutter or fibrillation) requiring medication

          -  No uncontrolled congestive heart failure

          -  No dyspnea at rest or with minimal exertion

          -  No severe pulmonary disease requiring supplemental oxygen

          -  No history of allergic reactions attributed to compounds of similar chemical or
             biological composition to 3-AP (Triapine®) and/or fludarabine phosphate

          -  No other life-threatening illness

          -  No history of mental deficits and/or psychiatric illness that would preclude study
             compliance

          -  No more than 4 prior induction regimens (3 cytotoxic chemotherapy regimens)

          -  At least 3 weeks since prior myelosuppressive cytotoxic agents (6 weeks for mitomycin
             C or nitrosoureas) and recovered

          -  At least 1 week since prior nonmyelosuppressive treatment

          -  At least 48 hours since prior noncytotoxic agents for peripheral blood leukemic cell
             count control, including but not limited to the following:

               -  Hydroxyurea

               -  Imatinib mesylate

               -  Interferon

               -  Mercaptopurine

               -  Cyclophosphamide

          -  At least 2 weeks since prior and no concurrent radiotherapy to treat cancer

          -  At least 1 week since prior biologic therapy, including hematopoietic growth factors
             (e.g., epoetin alfa, darbepoetin alfa, filgrastim [G-CSF], sargramostim [GM-CSF],
             interleukin-3, or interleukin-11)

          -  No other concurrent chemotherapy to treat cancer

          -  No concurrent immunotherapy to treat cancer

          -  No known glucose-6-phosphate dehydrogenase [G6PD) deficiency (G6PD screening required
             for high-risk groups (i.e., patients of African, Asian, or Mediterranean
             origin/ancestry)]

          -  No active heart disease

          -  No concurrent myeloid growth factors

          -  No active uncontrolled infection (Infections under active treatment and controlled
             with antibiotics are allowed)

          -  No chronic hepatitis
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Judith Karp</last_name>
    <role>Principal Investigator</role>
    <affiliation>Johns Hopkins University/Sidney Kimmel Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Johns Hopkins University/Sidney Kimmel Cancer Center</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21287</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Zeidner JF, Karp JE, Blackford AL, Smith BD, Gojo I, Gore SD, Levis MJ, Carraway HE, Greer JM, Ivy SP, Pratz KW, McDevitt MA. A phase II trial of sequential ribonucleotide reductase inhibition in aggressive myeloproliferative neoplasms. Haematologica. 2014 Apr;99(4):672-8. doi: 10.3324/haematol.2013.097246. Epub 2013 Dec 20.</citation>
    <PMID>24362550</PMID>
  </results_reference>
  <verification_date>June 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 26, 2006</study_first_submitted>
  <study_first_submitted_qc>September 26, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 28, 2006</study_first_posted>
  <results_first_submitted>April 23, 2014</results_first_submitted>
  <results_first_submitted_qc>April 23, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">May 21, 2014</results_first_posted>
  <last_update_submitted>December 16, 2014</last_update_submitted>
  <last_update_submitted_qc>December 16, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 6, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myelogenous, Chronic, BCR-ABL Positive</mesh_term>
    <mesh_term>Primary Myelofibrosis</mesh_term>
    <mesh_term>Leukemia, Myelomonocytic, Acute</mesh_term>
    <mesh_term>Leukemia, Myelomonocytic, Chronic</mesh_term>
    <mesh_term>Leukemia, Myelomonocytic, Juvenile</mesh_term>
    <mesh_term>Polycythemia</mesh_term>
    <mesh_term>Polycythemia Vera</mesh_term>
    <mesh_term>Thrombocytosis</mesh_term>
    <mesh_term>Thrombocythemia, Essential</mesh_term>
    <mesh_term>Philadelphia Chromosome</mesh_term>
    <mesh_term>Blast Crisis</mesh_term>
    <mesh_term>Myeloproliferative Disorders</mesh_term>
    <mesh_term>Leukemia, Myeloid, Accelerated Phase</mesh_term>
    <mesh_term>Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative</mesh_term>
    <mesh_term>Hypereosinophilic Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fludarabine</mesh_term>
    <mesh_term>Fludarabine phosphate</mesh_term>
    <mesh_term>Vidarabine</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Patient's presenting for treatment of a myeloproliferative disease were considered for participation.</recruitment_details>
      <pre_assignment_details>Once patient consented to treatment, treatment began shortly there after.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Triapine and Fludarabine Phosphate</title>
          <description>Patients receive 3-AP (Triapine®) IV over 4 hours followed by fludarabine phosphate IV over 30 minutes on days 1-5. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="35"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="35"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Arm I</title>
          <description>Patients receive 3-AP (Triapine®) IV over 4 hours followed by fludarabine phosphate IV over 30 minutes on days 1-5. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="35"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="65" spread="40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Response Rate Including Complete Response, Partial Response, and Hematological Improvement Assessed by Blood Cell Counts, Number of Blasts in Bone Marrow, and Clinical Evaluation</title>
        <description>Bone marrow aspiration and biopsies were performed prior to treatment, during week 3 of the first cycle, at the time of hematologic recovery from all cycles of therapy (defined as neutrophil count &gt;500/mm3 and platelets &gt;20,000/mm3 independently of transfusion), or at any time that leukemia regrowth was suspected. The overall response rate was defined as complete remission, partial remission, or hematologic improvement, lasting for ≥30 days. Given the different subsets of diseases, standardized response criteria were used for CMML (the Myelodysplastic Syndrome International Working Group criteria),33 CMML transforming to acute myeloid leukemia (standard AML response criteria) , accelerated MPN (Giles et al.), and transformation of MPN to secondary AML (Mascarenhas et al.).</description>
        <time_frame>Up to 4 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Arm I</title>
            <description>Patients receive 3-AP (Triapine®) IV over 4 hours followed by fludarabine phosphate IV over 30 minutes on days 1-5. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.</description>
          </group>
        </group_list>
        <measure>
          <title>Response Rate Including Complete Response, Partial Response, and Hematological Improvement Assessed by Blood Cell Counts, Number of Blasts in Bone Marrow, and Clinical Evaluation</title>
          <description>Bone marrow aspiration and biopsies were performed prior to treatment, during week 3 of the first cycle, at the time of hematologic recovery from all cycles of therapy (defined as neutrophil count &gt;500/mm3 and platelets &gt;20,000/mm3 independently of transfusion), or at any time that leukemia regrowth was suspected. The overall response rate was defined as complete remission, partial remission, or hematologic improvement, lasting for ≥30 days. Given the different subsets of diseases, standardized response criteria were used for CMML (the Myelodysplastic Syndrome International Working Group criteria),33 CMML transforming to acute myeloid leukemia (standard AML response criteria) , accelerated MPN (Giles et al.), and transformation of MPN to secondary AML (Mascarenhas et al.).</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="35"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Incidence of Grade 3 or 4 Drug-related Non-hematologic Toxicity as Assessed by NCI CTCAE v3.0</title>
        <time_frame>Up to 4 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Arm I</title>
            <description>Patients receive 3-AP (Triapine®) IV over 4 hours followed by fludarabine phosphate IV over 30 minutes on days 1-5. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence of Grade 3 or 4 Drug-related Non-hematologic Toxicity as Assessed by NCI CTCAE v3.0</title>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="35"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Arm I</title>
          <description>Patients receive 3-AP (Triapine®) IV over 4 hours followed by fludarabine phosphate IV over 30 minutes on days 1-5. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Infections</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Kidney injury</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperbilirubinemia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Tumor Lysis syndrome</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="35" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Allergic reaction</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Anaphylaxis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Fever</sub_title>
                <counts group_id="E1" events="11" subjects_affected="11" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Acidosis</sub_title>
                <counts group_id="E1" events="10" subjects_affected="10" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Elevated bilirubin</sub_title>
                <counts group_id="E1" events="14" subjects_affected="14" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Elevated creatinine</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Michael McDevitt, MD PhD</name_or_title>
      <organization>Sidney Kimmel Comprehensive Cancer Center</organization>
      <phone>410-955-9175</phone>
      <email>mmcdev1@jhmi.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

